Early access
Sign in
Taking people in PolandPhase 1

Testing JJP-1212 safety and immune response in people with skin or joint conditions

Tests the new medicine JJP-1212 in adults with linear IgA dermatosis or rheumatoid arthritis.

Key facts

Who runs it
Jjp Biologics Sp. z o.o.
Where
Warsaw, PolandSee the siteAlso in 1 other country, 1 site
Registry title
A clinical study to assess if a new investigational medicinal product called JJP-1212 is safe, tolerable and able to induce a specific immune response in humans
Status
Recruiting
Phase
Phase 1
People taking part
76 people, planned
Started
29 May 2024
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is testing whether a new investigational product, JJP-1212, is safe, tolerable and able to trigger a specific immune response in people. The record lists linear IgA dermatosis and rheumatoid arthritis, and healthy volunteers are accepted.

Age
18 years or older
Sex
Men and women can join.

Where in Poland

Also in 1 other country, 1 site

  • MTZ Clinical Research powered by PratiaWarsaw, PolandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Testing JJP-1212 safety and immune response in people with skin or joint conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 October 2026